Development of Diagnostic Method for clinical utility on Thyroid Carcinoma by Chemical assay
甲状腺癌化学检测临床诊断方法的发展
基本信息
- 批准号:17591343
- 负责人:
- 金额:$ 2.05万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2005
- 资助国家:日本
- 起止时间:2005 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Thymoglobulin (Tg) is produced by the thyroid with a molecular mass of 660,000 Dalton and a carbohydrate content of approximately 10%. Traditionally, the follow-up of differentiated thyroid carcinoma by measured serum Thymoglobulin. However, the concentration of thymoglobulin measured by immunoassay is greatly affected by presence of anti-Tg autoantiboies in sera.We developed of new diagnostic method for clinical utility on thyroid carcinoma by chemical assay using LCA lectin(LCA reactive Tg method). The study was conducted on 103 serum samples form healthily volunteers, 159 patients with benign thyroid tumor, 170 patients with thyroid carcinoma.The values of LCA reactive Tg method in patients with thyroid carcinoma was significantly lower than in patients those with benign thyroid tumor with serum Tg. The values of LCA reactive Tg method in serum may be useful for distinguishing between thyroid carcinoma and benign thyroid tumor.
胸腺球蛋白(Tg)由甲状腺产生,分子量为 660,000 道尔顿,碳水化合物含量约为 10%。传统上,分化型甲状腺癌的随访是通过测量血清胸腺球蛋白来进行的。然而,通过免疫测定法测得的胸腺球蛋白浓度受血清中抗Tg自身抗体存在的影响很大。我们通过使用LCA凝集素进行化学测定(LCA反应性Tg法),开发了临床实用的甲状腺癌新诊断方法。本研究对103名健康志愿者、159名甲状腺良性肿瘤患者、170名甲状腺癌患者的血清样本进行了研究。甲状腺癌患者的LCA反应性Tg法测定值显着低于甲状腺良性肿瘤患者的血清Tg值。血清中LCA反应性Tg法的值可能有助于区分甲状腺癌和良性甲状腺肿瘤。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Clinical Utility of Lens culinaris Agglutinin-Reactive Thyroglobulin Ratio in Serum for Distinguishing Benign from Mlignant Codition of Thyroid
血清中菜豆凝集素反应性甲状腺球蛋白比值鉴别甲状腺良恶性疾病的临床应用
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Shimizu K;kato R;et al.
- 通讯作者:et al.
抗サイログロブリン自己抗体が認識するTg抗原エピトープの研究.
抗甲状腺球蛋白自身抗体识别的 Tg 抗原表位的研究。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:亀子文子;天川雅夫;加藤亮二
- 通讯作者:加藤亮二
Disrimination of Thyroglobulin form Thyroid Carcinoma Tissue and from benign thyroid Tissues with Use of Competitive Assay between Lectin and Anti-Thyroglobulin Antibody
使用凝集素和抗甲状腺球蛋白抗体之间的竞争性测定区分甲状腺球蛋白来自甲状腺癌组织和良性甲状腺组织
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Shimizu K;kato R;et al.
- 通讯作者:et al.
The Clinical Utility of Lens culinaris Agglutinin-Reactive Thymoglobulin Ratio in Serum for Distinguishing Benign from Malignant Condition of Thyroid
血清中菜豆凝集素反应性胸腺球蛋白比值鉴别甲状腺良恶性的临床应用
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Shimizu;K.Kato;R et al.
- 通讯作者:R et al.
Discrimination of Thymoglobulin form Thyroid Carcinoma Tissue and from benign thyroid Tissues with Use of Competitive Assay between Lectin and Anti-Thymoglobulin Antibody
使用凝集素和抗胸腺球蛋白抗体之间的竞争测定法区分甲状腺癌组织和良性甲状腺组织中的胸腺球蛋白
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Shimizu;K.Kato;R et al.
- 通讯作者:R et al.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KATO Ryoji其他文献
KATO Ryoji的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KATO Ryoji', 18)}}的其他基金
Development of a New Diagnostic Method for Thyroid Carcinoma by Measurement of Lectin Inhibitory Thyroglobulin
通过测量凝集素抑制性甲状腺球蛋白开发甲状腺癌新诊断方法
- 批准号:
15591370 - 财政年份:2003
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of Detection System for Thyroid Carcinoma Specific Antigen and its Function Analysis
甲状腺癌特异性抗原检测系统的研制及其功能分析
- 批准号:
13671270 - 财政年份:2001
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Exploration of biomarkers based on genomic information and tumor immune microenvironment of thyroid cancer
基于甲状腺癌基因组信息和肿瘤免疫微环境的生物标志物探索
- 批准号:
23K19516 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
A Pilot Feasibility Study of an Intervention to Decrease Overtreatment of Low-risk Thyroid Cancer
减少低危甲状腺癌过度治疗的干预措施试点可行性研究
- 批准号:
10729147 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Cancer-associated fibroblasts promote thyroid cancer malignancy through Wnt signaling
癌症相关成纤维细胞通过 Wnt 信号传导促进甲状腺癌恶性
- 批准号:
10677942 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Targeting Ferroptosis in BRAF (V600E) Mutant Anaplastic Thyroid Cancer
靶向 BRAF (V600E) 突变型甲状腺未分化癌中的铁死亡
- 批准号:
10721967 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
The Effect of WTC Exposure on Thyroid Cancer in the Survivor Population
WTC 暴露对幸存者人群甲状腺癌的影响
- 批准号:
10749691 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Elucidation of molecular mechanisms of occurrence of anaplastic thyroid cancer using gene mutation analysis and comprehensive gene expression analysis
利用基因突变分析和综合基因表达分析阐明甲状腺未分化癌发生的分子机制
- 批准号:
23K08067 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Assay to Individualize Resensitization of Iodine-Refractory Thyroid Cancer
碘难治性甲状腺癌个体化再敏化的新方法
- 批准号:
10612661 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
The development of a technology-based information support intervention (iSupport) among patients with differentiated thyroid cancer post radioactive iodine therapy
针对放射性碘治疗后分化型甲状腺癌患者开发基于技术的信息支持干预 (iSupport)
- 批准号:
10581121 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Development of a risk assessment system using minimally invasive comprehensive preoperative genetic testing for thyroid cancer
甲状腺癌术前微创综合基因检测风险评估系统的开发
- 批准号:
22K07476 - 财政年份:2022
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




